SCHEMBL8773066

SCHEMBL8773066

O=C1C=C(Cl)C(=O)c2ccc(Cl)cc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100A4 P26447 2/20 0.56
HSP90AA1 P07900 1/20 0.47
PTPN1 P18031 1/20 0.46
PPOX P50336 1/20 0.45
PTPN11 Q06124 1/20 0.42
AURKA O14965 1/20 0.42
AURKB Q96GD4 1/20 0.42
CES1 P23141 3/20 0.41
TGM2 P21980 1/20 0.41
USP8 P40818 2/20 0.41
USP7 Q93009 2/20 0.41
METAP1 P53582 1/20 0.39
USP47 Q96K76 1/20 0.38
PTPRC P08575 1/20 0.37
ITGA1 P56199 1/20 0.36
CHEK1 O14757 1/20 0.35
DAPK3 O43293 1/20 0.35
MAP4K4 O95819 1/20 0.35
RET P07949 1/20 0.35
PIM1 P11309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9629435 0.92 S100A4 (0.61) S100A4HSP90AA1PTPN1PPOXPTPN11
SCHEMBL8662178 0.81 S100A4 (0.44) S100A4HSP90AA1PTPN1PPOXPTPN11
SCHEMBL9713573 0.81 MAOA (0.55) S100A4AURKAAURKB
SCHEMBL7815913 0.80 MAOA (0.53) AURKAAURKBCES1USP8USP7
SCHEMBL976245 0.80 HSP90AA1 (0.53) S100A4HSP90AA1PTPN1PPOXPTPN11
SCHEMBL23271753 0.80 ESR2 (0.57) AURKAAURKBPTPRCDYRK1A
SCHEMBL9628267 0.80 PTPN1 (0.44) S100A4PTPN1AURKAAURKBCES1
SCHEMBL23271777 0.80 S100A4 (0.52) S100A4HSP90AA1PTPN1PPOXPTPN11
SCHEMBL9628309 0.80 S100A4 (0.52) S100A4AURKAAURKBCES1TGM2
SCHEMBL9627970 0.80 ALDH1A1 (0.57) S100A4HSP90AA1PTPN1PPOXPTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11767308-B2 Method of stabilizing perfluorodioxolane compound, perfluorodioxolane compound-containing composition and method of producing perfluorodioxolane compound polymer TOSOH CORPORATION (JP) 2023-09-26 US disclosed
US-11613509-B2 Radical polymerization control agent and radical polymerization control method KAWASAKI KASEI CHEMICALS LTD. (JP) 2023-03-28 US disclosed
US-20210122692-A1 RADICAL POLYMERIZATION CONTROL AGENT AND RADICAL POLYMERIZATION CONTROL METHOD KAWASAKI KASEI CHEMICALS LTD. (JP) 2021-04-29 US disclosed
EP-0439585-B1 IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS MAG GEORG MAYRHOFER & CO OHG (AT) 1997-10-29 EP disclosed
US-5196478-A Polystyrene, assays EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) 1993-03-23 US disclosed
US-5155132-A Nonsteroidal antiinflammatory agents; treating psoriasis SYNTEX (U.S.A.) INC. (US) 1992-10-13 US disclosed
US-5134161-A Enzyme inhibitors for skin disorders, antiinflammatory agents SYNTEX (U.S.A.) INC. (US) 1992-07-28 US disclosed
US-5091558-A Topical administeration SYNTEX (U.S.A.) INC. (US) 1992-02-25 US disclosed
US-5089657-A Topical antiinflammatory agents SYNTEX (U.S.A.) INC. (US) 1992-02-18 US disclosed
EP-0439585-A1 IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS. EPIPHARM ALLERGIE SERVICE (AT) 1991-08-07 EP disclosed
WO-1991002768-A1 IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) 1991-03-07 WO disclosed
US-4786652-A TOPICAL ADMINISTRATION SYNTEX (U.S.A.) INC. (US) 1988-11-22 US disclosed
EP-0282006-A1 Naphtalene anti-psoriatic agents SYNTEX (U.S.A.) INC. (US) 1988-09-14 EP disclosed
EP-0282056-A2 Naphthalene anti-psoriatic agents SYNTEX (U.S.A.) INC. (US) 1988-09-14 EP disclosed
EP-0150831-B1 NAPHTHALENE ANTI-PSORIATIC AGENTS SYNTEX (U.S.A.) INC. (US) 1988-08-10 EP disclosed
US-4758587-A Naphthalene anti-psoriatic agents SYNTEX (U.S.A.) INC. (US) 1988-07-19 US disclosed
EP-0150831-A2 Naphthalene anti-psoriatic agents SYNTEX (U.S.A.) INC. (US) 1985-08-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11767308-B2 Method of stabilizing perfluorodioxolane compound, perfluorodioxolane compound-containing composition and method of producing perfluorodioxolane compound polymer PFAS, PFN1, PFKFB1 S100A4 3598/4885HSP90AA1 2762/4885PTPN1 796/4885
US-11613509-B2 Radical polymerization control agent and radical polymerization control method PPOX, NOX4, CROCC S100A4 1775/4885HSP90AA1 2180/4885PTPN1 1787/4885
US-20210122692-A1 RADICAL POLYMERIZATION CONTROL AGENT AND RADICAL POLYMERIZATION CONTROL METHOD PPOX, NOX4, CROCC S100A4 1775/4885HSP90AA1 2180/4885PTPN1 1787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.